Home » Newsletters » BioWorld Science

BioWorld Science

June 27, 2003

View Archived Issues

Pfizer integrates Pharmacia and reports on pipeline progress

Gemzar/Taxol approved in Finland for metastatic breast cancer

FDA extends Cidecin review period

Enrollment completed in ONTARGET trial of Micardis

DW-1350 inhibits bone resorption and enhances bone formation

Limited antitumor activity for SU-6668 monotherapy in multiple myeloma

Pharmacokinetic data support use of oral deferasirox in transfusional hemosiderosis

Finasteride may reduce the risk of prostate cancer

Good safety and efficacy described for rasburicase in cancer patients with hyperuricemia

Once-daily dosing feasible for canertinib in advanced solid tumors

Lilly patent covers novel orally available LY-354740 prodrugs

Novel IMP dehydrogenase inhibitors under study at Celltech R&D

AstraZeneca presents new ERbeta ligands for AD, anxiety, depression, osteoporosis, etc.

Cyclic peptide with sst receptor-agonist activity identified by SCRAS scientists

Cortex researchers present new AMPA modulators with cognition-enhancing properties

New MMP/aggrecanase inhibitors identified by Pharmacia (Pfizer) team

Merck & Co. describes new MCH1 antagonists, their preparation and use

MethylGene and Merck Frosst enter agreement for antibiotic resistance program

Novartis Ophthalmics obtains development and marketing license for Lucentis

Demegen and Dow form development collaboration

Cytogen signs agreement to reacquire marketing rights to Quadramet

FIT Biotech and IAVI team up to evaluate GTU-MultiHIV for AIDS prevention

Genzyme exercises option to acquire 50% interest in DX-88 for HAE

Preclinical findings for antiangiogenic botanical IDN-5390

Enbrel improves plaque psoriasis symptoms in phase III study

DARPA grant will fund development of CpG TLR9 agonists for use with anthrax vaccine

Good safety and pharmacokinetic profile reported for UR-8880 in healthy volunteers

Combination therapy including bortezomib effective in colorectal cancer model

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...